Phillip Gomez, SIGA CEO

On the back of SIGA Tech­nolo­gies' win with the FDA, the mon­key­pox virus sees the com­pa­ny spring­ing to fur­ther ac­tion

As the cas­es of mon­key­pox now sit at well over 100 world­wide and have spread to mul­ti­ple con­ti­nents, the or­ders for any type of vac­cine against mon­key­pox are see­ing na­tions and med­ical bod­ies look­ing to get their hands on any­thing and every­thing. And now SIGA Tech­nolo­gies seems to be get­ting in on the ac­tion.

Ac­cord­ing to Eu­ronews, SIGA Tech­nolo­gies, a phar­ma­ceu­ti­cal com­pa­ny that is fo­cused on pro­vid­ing med­ical coun­ter­mea­sures to bi­o­log­i­cal and chem­i­cal at­tacks, is now in talks with sev­er­al Eu­ro­pean au­thor­i­ties look­ing to stock­pile its an­tivi­ral that can counter mon­key­pox. The drug known as tecovir­i­mat or Tpoxx was ap­proved by the FDA in 2018 as a vac­cine for small­pox but was ap­proved by the Eu­ro­pean Med­i­cines Agency to al­so act against mon­key­pox, cow­pox and com­pli­ca­tions from im­mu­niza­tion with vac­cinia.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.